US › Healthcare

Replimune Group Inc (REPL)

US · Healthcare · Biotechnology

$11.92+0.08%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-73.2M
Profit YoY
+1.2%
EPS
$-0.76
EPS estimate
$-0.73

EPS came in at -0.76 against a street estimate of -0.73 — a miss of 4.1%.

Key statistics

Market cap
$941.1M
Forward P/E
0.0
P/B
5.66
Book value
$2.01
EPS (TTM)
$-3.38
52-week high
$12.60
52-week low
$1.50
50-day MA
$9.26
200-day MA
$7.83
Beta
0.87

Analyst view

Analysts rate Replimune Group Inc a buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $12.00.

Shareholding

Insiders
1.99%
Institutions
112.08%

Largest institutional holders

FundStake
Baker Bros Advisors LP13.15%
T. Rowe Price Associates, Inc.9.67%
RTW INVESTMENTS, LLC8.76%
BlackRock Inc7.43%
Suvretta Capital Management, LLC5.02%
State Street Corp4.50%
FCPM III SERVICES BV3.34%
Vanguard Capital Management, LLC3.28%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Replimune Group Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.